-
公开(公告)号：US20100137401A1
公开(公告)日：2010-06-03
申请号：US12698261
申请日：2010-02-02
申请人： Wenqing Yao , Colin Zhang , Jincong Zhuo , Meizhong Xu , Konstantinos Agrios , Brian Metcalf
发明人： Wenqing Yao , Colin Zhang , Jincong Zhuo , Meizhong Xu , Konstantinos Agrios , Brian Metcalf
IPC分类号： A61K31/404 , C07C233/07 , A61K31/165 , C12N9/99 , C07D307/22 , A61K31/341 , C07D209/18 , C07D319/16 , A61K31/357 , C07C233/06 , C07C233/05 , A61P3/10 , A61P3/04 , A61P3/06 , A61P9/00 , A61P9/10
CPC分类号： C07C233/11 , C07C233/13 , C07C233/19 , C07C233/22 , C07C233/23 , C07C235/22 , C07C323/60 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/28 , C07C2602/42 , C07D209/14 , C07D209/16 , C07D307/22 , C07D319/20
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
公开(公告)号：US07462624B2
公开(公告)日：2008-12-09
申请号：US11766990
申请日：2007-06-22
申请人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
发明人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
IPC分类号： A01N43/54 , A61K31/505 , C07D239/00 , C07D471/00 , C07D487/00 , C07D491/00
CPC分类号： C07D487/14 , C07D403/14 , C07D487/04
摘要： The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
摘要翻译： 本发明涉及作为HM74a受体的激动剂的嘌呤酮衍生物。 还提供了使用本文化合物及其药学上可接受的盐来治疗疾病的组合物和方法。
-
33.发明申请公开(公告)号：US20060004018A1
公开(公告)日：2006-01-05
申请号：US11167816
申请日：2005-06-27
申请人： Chu-Biao Xue , Changsheng Zheng , Hao Feng , Michael Xia , Joseph Glenn , Ganfeng. Cao , Brian Metcalf
发明人： Chu-Biao Xue , Changsheng Zheng , Hao Feng , Michael Xia , Joseph Glenn , Ganfeng. Cao , Brian Metcalf
IPC分类号： A61K31/496 , A61K31/4545 , C07D45/14
CPC分类号： C07D405/14 , C07D309/14 , C07D405/12
摘要： The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
摘要翻译： 本发明涉及式I化合物：其是趋化因子受体的调节剂。 本发明的化合物及其组合物可用于治疗与趋化因子受体表达和/或活性相关的疾病。
-
公开(公告)号：US20050288338A1
公开(公告)日：2005-12-29
申请号：US11159862
申请日：2005-06-23
申请人： Wenqing Yao , Colin Zhang , Meizhong Xu , Jincong Zhuo , Chunhong He , Brian Metcalf
发明人： Wenqing Yao , Colin Zhang , Meizhong Xu , Jincong Zhuo , Chunhong He , Brian Metcalf
IPC分类号： A61K31/165 , A61K31/44 , A61K31/445 , C07C233/58 , C07C233/60 , C07C233/63 , C07C235/40 , C07C317/44 , C07C323/61 , C07D207/14 , C07D209/14 , C07D211/58 , C07D213/30 , C07D213/38 , C07D213/81 , C07D307/22 , C07D307/38 , C07D309/14 , C07D319/20
CPC分类号： C07C233/58 , C07C233/59 , C07C233/60 , C07C233/63 , C07C235/40 , C07C317/44 , C07C323/61 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/02 , C07C2602/08 , C07C2602/10 , C07C2602/42 , C07D207/14 , C07D209/14 , C07D211/58 , C07D211/96 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/81 , C07D295/205 , C07D307/22 , C07D307/33 , C07D307/38 , C07D309/14 , C07D319/20
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及1型11-β羟基类固醇脱氢酶抑制剂，盐皮质激素受体MR的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与1-β羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病的表达或活性相关的各种疾病。
-
公开(公告)号：US20050288317A1
公开(公告)日：2005-12-29
申请号：US11159863
申请日：2005-06-23
申请人： Wenqing Yao , Yanlong Li , Meizhong Xu , Jincong Zhuo , Colin Zhang , Brian Metcalf
发明人： Wenqing Yao , Yanlong Li , Meizhong Xu , Jincong Zhuo , Colin Zhang , Brian Metcalf
IPC分类号： A61K31/40 , A61K31/445 , A61K31/4709 , A61K31/4745 , C07D211/96 , C07D401/04 , C07D401/06 , C07D401/14 , C07D491/10
CPC分类号： C07D491/10 , C07D211/96 , C07D401/04 , C07D401/06 , C07D401/14
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及1型11-β羟基类固醇脱氢酶抑制剂，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与1-β羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病的表达或活性相关的各种疾病。
-
36.发明申请3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors 有权3-（4-杂芳基环己基氨基）环戊烷甲酰胺作为趋化因子受体的调节剂公开(公告)号：US20050267146A1
公开(公告)日：2005-12-01
申请号：US11125647
申请日：2005-05-10
申请人： Chu-Biao Xue , Changsheng Zheng , Ganfeng Cao , Hao Feng , Michael Xia , Rajan Anand , Joseph Glenn , Brian Metcalf
发明人： Chu-Biao Xue , Changsheng Zheng , Ganfeng Cao , Hao Feng , Michael Xia , Rajan Anand , Joseph Glenn , Brian Metcalf
IPC分类号： A61K31/47 , A61K31/4745 , C07D217/06 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12 , C07D471/02 , C07D471/04
CPC分类号： C07D471/04 , C07D217/06 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12
摘要： The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
摘要翻译： 本发明涉及式I化合物：其是趋化因子受体的调节剂。 本发明的化合物及其组合物可用于治疗与趋化因子受体表达和/或活性相关的疾病。
-
公开(公告)号：US08110581B2
公开(公告)日：2012-02-07
申请号：US12252700
申请日：2008-10-16
申请人： Wenqing Yao , Chunhong He , David M. Burns , Jincong Zhuo , Meizhong Xu , Colin Zhang , Ding-Quan Qian , Brian Metcalf
发明人： Wenqing Yao , Chunhong He , David M. Burns , Jincong Zhuo , Meizhong Xu , Colin Zhang , Ding-Quan Qian , Brian Metcalf
IPC分类号： C07D471/10 , A61K31/4439
CPC分类号： C07D471/10
摘要： The present invention relates to inhibitors of 11-βhydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-βhydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及1型11型羟基类固醇脱氢酶抑制剂，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病的表达或活性相关的各种疾病。
-
公开(公告)号：US08039478B2
公开(公告)日：2011-10-18
申请号：US12263990
申请日：2008-11-03
申请人： Changsheng Zheng , Chu-Biao Xue , Ganfeng Cao , Michael Xia , Anlai Wang , Hai Fen Ye , Brian Metcalf
发明人： Changsheng Zheng , Chu-Biao Xue , Ganfeng Cao , Michael Xia , Anlai Wang , Hai Fen Ye , Brian Metcalf
IPC分类号： A01N43/54 , A61K31/505 , C07D239/00 , C07D487/00
CPC分类号： C07D487/14
摘要： The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
-
公开(公告)号：US08039471B2
公开(公告)日：2011-10-18
申请号：US12327313
申请日：2008-12-03
申请人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Fenglei Zhang , Brian Metcalf
发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Fenglei Zhang , Brian Metcalf
IPC分类号： A61K31/497 , A61K31/51 , A61K31/435 , C07D241/36 , C07D401/02 , C07D491/20 , C07D211/32
CPC分类号： A61K31/496 , A61K31/40 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/495 , A61K31/4985 , A61K31/55 , A61K31/551 , C07D221/20 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04
摘要： The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
摘要翻译： 本发明提供了式I或式II的化合物：对映异构体，非对映异构体，前药，溶剂合物，代谢物或药学上可接受的盐，其中在本文中提供了组成变量。 式I和II的化合物是金属蛋白酶的调节剂，并且可用于治疗与金属蛋白酶活性相关的疾病，例如关节炎，癌症，心血管疾病，皮肤病，炎症和变态反应。
-
公开(公告)号：US07902205B2
公开(公告)日：2011-03-08
申请号：US12237794
申请日：2008-09-25
申请人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
发明人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
IPC分类号： A01N43/54 , A61K31/505 , C07D491/00
CPC分类号： C07D487/14 , C07D403/14 , C07D487/04
摘要： The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
-
-
-
-
-
-
-
-
-
搜索结果
49 条记录 (耗时 0.045 秒)
